The COPD Foundation is extremely pleased to announce that a new clinical biomarker, plasma fibrinogen, has been approved for use in interventional clinical trials in patients with chronic obstructive pulmonary disease, the nation’s 3rd leading cause of death. This is the first COPD biomarker to receive qualification by the U.S. Food and Drug Administration (FDA)…
There may be 35 million older Americans with undiagnosed lung disease due to cigarette smoking, a new study suggests. They don’t meet the criteria for a diagnosis of chronic obstructive pulmonary disease (COPD), but they still suffer significant lung disease and impairment, the researchers report in JAMA Internal Medicine. “We think we can increase their…
The higher the power of an e-cigarette, the higher the concentrations of potentially hazardous substances the device produces, including acetaldehyde, acrolein, and formaldehyde. Those are among the findings presented at an international conference of the American Thoracic Society by lead study author Dr. Daniel Sullivan, an internal medicine resident at the University of Texas Southwestern…
In the Issue of the New England Journal of Medicine an investigation of the role of financial incentives and nudges in promoting smoking cessation, with particular emphasis on the importance of loss aversion and pre-commitment is explored. In the past 40 years, we have seen a revolution in thinking about thinking. The central idea is…
MD Spiro prides itself on not only offering incredible spirometry products for your practice, but also prides itself on providing articles and industry updates for our customers. Below is a new study showing you trends, R&D progress, and predicted revenues in Asthma and COPD Therapies. So where’s the asthma and COPD therapies market heading? Visiongain’s…
Today, is Earth Day. A statement released by the White House outlines an initiative to combat the health-related effects of climate change, with an emphasis on chronic obstructive pulmonary disease (COPD) and asthma. “The Centers for Disease Control and Prevention (CDC) is releasing an Adaptation in Action Report highlighting successful actions state and local…
Diabetics now have a new option thanks to the breakthrough new medication AFREZZA®, an inhaled insulin now available by prescription. The labeling for AFREZZA®, mandates spirometry testing (specifically FEV1) to rule out chronic lung disease prior to initiating therapy, six months after initiation and every year thereafter1. MD Spiro offers a number of spirometer options…
Reducing the risks of e-cigarettes to smokers, encouraging the smoking-cessation potential, and restricting access by nonsmokers offer a regulatory trifecta that can be implemented immediately, according to a former FDA official. The “roadmap” to effective regulation hinges on implementation of the pending FDA deeming rule, which is expected to go into effect later this year….